A New Medication for Weight Loss
Obesity is an increasingly prevalent problem in developed countries, and a safe and effective medication for weight loss is eagerly sought. Most weight loss medications have been plagued by serious side effects.
Fenfluramine, a medication used with phentermine in the popular “fen-phen” combination in the 1990s, was found to cause serious heart valve abnormalities and was withdrawn from the market. The two prescription medications currently available are only modestly effective and each suffers from side effects that limit its use. Sibutramine (Meridia) can elevate blood pressure and increase the risk of stroke and heart attack. Orlistat (by prescription as Xenical, or over the counter as Alli) causes greasy stools and diarrhea. These side effects make further weight gain seem like an appealing alternative.
A study in this week’s New England Journal of Medicine raises hopes for a new, safer weight loss medicine. The study randomized over 3,000 overweight and obese patients to lorcaserin and to placebo for one year. Importantly, all patients received ongoing counseling regarding diet and exercise. Patients were instructed to engage in 30 minutes of moderate exercise daily and were taught to eat a diet containing 600 calories below their daily energy requirements.
At the end of the first year the group on lorcaserin lost an average of 13 lb, while the placebo group lost an average of 5 lb. In the second year of the study, the patients on placebo for the first year continued receiving placebo. The patients on lorcaserin during the first year were again randomized to receive lorcaserin or placebo the second year. The patients who received lorcaserin the second year maintained the weight loss achieved during the first year, while the patients who received lorcaserin the first year and placebo the second year regained weight until their weight matched the group that was always on placebo.
Most tantalizing, however, was the safety profile. Side effects were few, and tolerable. Headache, dizziness and nausea were most common. Since lorcaserin is in the same family as fenfluramine (though designed specifically to avoid the valvular side effect) the patients were monitored for valvular abnormalities. The lorcaserin group did not develop valve problems any more frequently than in the placebo group.
The additional weight loss in the lorcaserin was not dramatic, suggesting that lorcaserin is no more effective (or maybe a little less effective) than sibutramine and orlistat. But this preliminary study suggests that it is much safer than the existing alternatives. If larger studies replicate this result, it may be a reasonable addition to diet and exercise.
New England Journal of Medicine article: ” target=”_blank”>Drug Management of Obesity — Efficacy versus Safety